The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
批准号:
10284166
负责人:
Christopher James Gibson
金额:
$21.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2026-08-31
关键词:
Acute Myelocytic LeukemiaAdvisory CommitteesAffectAllogenicAreaBiologic CharacteristicBiological AssayBiological ProcessBiologyBiometryBone MarrowCardiovascular DiseasesCaringCellsCharacteristicsClinicalClonal EvolutionClonal ExpansionCollaborationsCommunitiesCyclophosphamideDana-Farber Cancer InstituteDataData ScienceDevelopment PlansDiseaseDisease remissionDonor SelectionDonor personEngraftmentEnvironmentGenesGenomicsGoalsHematologic NeoplasmsHematopoiesisHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHistologicImmuneImmune EvasionImmune systemImmunologic SurveillanceImmunologicsImmunologyImpairmentIndividualInflammatoryInterventionInvestigationLeukocytesMediatingMentorshipModalityMutateMutationMyeloid CellsOutcomeOutputPathogenicityPathway interactionsPatientsPatternPhysiciansPopulationRecurrent diseaseRelapseResearchResearch PersonnelResidual stateRiskSamplingScientistShapesSignal TransductionSomatic MutationStem cell transplantT-Cell DevelopmentT-LymphocyteT-Lymphocyte SubsetsTechniquesTestingTimeToxic effectTrainingTransplant RecipientsTransplantationWorkadverse outcomeage relatedbasecancer cellcareercareer developmentcell typecurative treatmentscytokinecytopeniadisorder riskexhaustionexperimental studygraft failuregraft functiongraft vs leukemia effecthematopoietic cell transplantationimprovedimproved outcomeinsightleukemia relapsemutantnovelnovel strategiesnovel therapeutic interventionpost-transplantpressurerelapse risksingle cell technologysuccess
中文摘要
项目概要/摘要
造血细胞移植(HCT)是恶性血液病患者的重要治疗手段
(HM)。它的成功取决于供体造血细胞建立长期造血的能力,
免疫介导的残留恶性细胞消除。克隆性造血(CH)是一种与年龄相关的
一种可检测到的体细胞突变改变了生物学功能和炎症输出的疾病,
在造血细胞和非移植人群中,与不良结局一致相关。通过
通过研究1727对HCT供受者,我发现CH在供者中很常见,
DNMT 3A基因是最常见的变异。我的初步数据显示供体DNMT 3A-CH是
与改善的全球接受者结局相关,由HM复发风险降低介导,但也
增加了一部分接受者移植失败的风险。根据这些数据和已知的函数,
DNMT 3A在造血细胞中的作用,我假设供体DNMT 3A-CH I在HCT受者中观察到的作用
是由于DNMT 3A突变的长期造血干细胞的植入和随后的功能改变
在成熟的DNMT 3A突变型白细胞亚群中,特别是T细胞中。为了验证这个假设,我提出以下建议
两个目的:(1)确定HCT后DNMT 3A-CH对正常和受损造血的作用。我会
使用基因组、免疫表型和单细胞技术来定义特征,包括细胞
区室,移植到受体中的供体DNMT 3A突变。然后我将着重阐述
(2)明确DNMT 3A-CH在供体肾移植中的作用。
移植后植入的T细胞。我将使用基因组、免疫表型和单细胞技术,
确定供体DNMT 3A突变对受体中T细胞组成和功能的影响,
移植,特别关注DNMT 3A突变如何调节T细胞耗竭的发展。
然后,我将具体评估T细胞中供体DNMT 3A突变如何影响免疫逃避途径
急性髓细胞白血病复发病例中使用。从这些研究中获得的信息将提供
对移植后造血和免疫监视生物学的新见解,
供体选择和策略的影响,以增加移植物抗白血病的效果。灯会随着
根据提议的实验,我概述了一个五年职业发展计划,目标是成为一名
翻译移植研究的独立研究员。我召集了一个全球性的咨询委员会
造血、移植免疫学和生物统计学方面的公认专家,提供实验输入
在这些领域的具体培训。丹娜-法伯癌症研究所,拥有一项杰出的研究
一个社区,并有长期的记录,为独立的医生科学家成功的导师,是一个理想的
这是我完成这些实验和实现我的短期和长期职业目标的环境。
英文摘要
PROJECT SUMMARY/ABSTRACT
Hematopoietic cell transplant (HCT) is an important treatment modality for patients with hematologic malignancy
(HM). Its success depends on the ability of donor hematopoietic cells to establish long-term hematopoiesis and
immunologically mediated elimination of residual malignant cells. Clonal hematopoiesis (CH) is an age-related
condition in which detectable somatic mutations alter the biologic function and inflammatory output of
hematopoietic cells, and in non-transplant populations is uniformly associated with adverse outcomes. By
studying 1727 HCT donor-recipient pairs, I found that CH in donors is common and that inactivating mutations
in the gene DNMT3A are the most frequent alterations. My preliminary data shows that donor DNMT3A-CH is
associated with improved global recipient outcomes, mediated by a reduced risk of HM relapse, but also
increases the risk of graft failure in a subset of recipients. Based on these data and the known function of
DNMT3A in hematopoietic cells, I hypothesize that the effects of donor DNMT3A-CH I observe in HCT recipients
are due to engraftment of DNMT3A-mutated long-term hematopoietic stem cells and subsequent altered function
in mature DNMT3A-mutant leukocyte subsets, particularly T cells. To test this hypothesis, I propose the following
two aims: (1) Determine the effect of DNMT3A-CH on normal and impaired hematopoiesis following HCT. I will
use genomic, immunophenotypic, and single-cell technologies to define the characteristics, including cellular
compartment, of donor DNMT3A mutations that engraft in recipients. I will then focus on elucidating the biology
of graft failure developing in recipients of donor DNMT3A-CH. (2) Define the effect of DNMT3A-CH in donor-
engrafted T-cells after transplantation. I will use genomic, immunophenotypic, and single-cell techniques to
determine the effect of donor DNMT3A mutations on T-cell composition and function in recipients after
transplantation, focusing specifically on how DNMT3A mutations modulate the development of T-cell exhaustion.
I will then specifically assess how donor DNMT3A mutations in T cells affect the pathways of immune evasion
utilized by relapsing cases of acute myeloid leukemia. The information gained from these studies will provide
new insights into the biology of post-transplant hematopoiesis and immune surveillance that could have profound
implications for donor selection and strategies to augment the graft-versus-leukemia effect. In concert with the
proposed experiments, I have outlined a five-year career development plan aimed at the goal of becoming an
independent investigator in translational transplant research. I have assembled an advisory committee of globally
recognized experts in hematopoiesis, transplant immunology, and biostatistics, to provide experimental input
and specific training in these fields. Dana-Farber Cancer Institute, which harbors an outstanding research
community and has a long track record for successful mentorship of independent physician scientists, is an ideal
environment for completion of these experiments and realization of my short and long-term career goals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
-
批准号:10471977
-
项目类别:
-
资助金额:$21.99万
-
财政年份:2021
-
负责人:Christopher James Gibson
-
依托单位:
海外基金